GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.85
−3.17%Year over year
Reported trailing growth
- Revenue
- +49.1%
- EBITDA
- -73.5%
- EBIT
- -59.5%
- EPS
- -14.3%
- Free cash flow
- -29.8%
- Operating cash flow
- -44.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -4.4%
- EBITDA
- —
- EBIT
- -44.4%
- Net income
- -55.6%
- EPS
- -50.0%
- Free cash flow
- -7.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026